USP General Notices and General Test Chapters: Interpretations and Misinterpretations

While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Speedier implementation of the Post-Approval Change Management Protocol is essential for it to have a positive effect on supply security, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

The trade show is expected to draw 35,000 attendees to a show floor netting more than 1 million square feet.

The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as well as facilities in California, Indiana, Maryland, Massachusetts, and Texas.